IntroductionPsoriasis and pemphigus are two chronic inflammatory immune mediated cutaneous disorders. Rituximab (MabThera, Rituxan) is a chimeric murine/human anti-CD20 monoclonal antibody known as a potential drug for treatment of pemphigus vulgaris. It is administrated via intravenous infusion (1). Here we present a case of a 48-years-old patient affected with pemphigus vulgaris and developed psoriatic plaques on her scalp, trunk and arms four months after the second course of rituximab.